Cargando…

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

INTRODUCTION: Despite the high prevalence of non-alcoholic fatty liver disease (NAFLD) and its associated co-morbidities, no efficient treatment in a high percentage of individuals is available. Beneficial effects of sodium–glucose co-transporter 2 inhibitors on fatty liver have been investigated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taheri, Hoda, Malek, Mojtaba, Ismail-Beigi, Faramarz, Zamani, Farhad, Sohrabi, Masoudreza, Reza babaei, Mohammad, Khamseh, Mohammad E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547956/ https://www.ncbi.nlm.nih.gov/pubmed/32975679 http://dx.doi.org/10.1007/s12325-020-01498-5

Ejemplares similares

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Chehrehgosha, Haleh, et al.
Publicado: (2021)

Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial
por: Attaran, Fereshte, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease and compromised endothelial function in people with type 2 diabetes
por: Montazeri, Zeinab, et al.
Publicado: (2023)

A View Beyond HbA1c: Role of Continuous Glucose Monitoring
por: Chehregosha, Haleh, et al.
Publicado: (2019)

Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature
por: Rahimi, Leili, et al.
Publicado: (2020)

Clinical, Endoscopic, and Histopathological Aspects of Sigmoid Actinomycosis; A Case Report and Literature Review
por: Zamani, Farhad, et al.
Publicado: (2015)

Acute liver failure after vaccination against of COVID-19; a case report and review literature
por: Sohrabi, Masoudreza, et al.
Publicado: (2021)

Esophageal Lichen Planus Stricture
por: Zamani, Farhad, et al.
Publicado: (2019)

Melatonin Levels in Patients with Nonalcoholic Fatty Liver Disease Compared with Healthy Individuals according to Fibrosis Level
por: Sohrabi, Masoudreza, et al.
Publicado: (2021)

Is melatonin associated with pro-inflammatory cytokine activity and liver fibrosis in non-alcoholic fatty liver disease (NAFLD) patients?
por: Sohrabi, Masoudreza, et al.
Publicado: (2021)

Serum Alkaline Phosphate Level Associates with Metabolic Syndrome Components Regardless of Non-Alcoholic Fatty Liver; A Population-Based Study in Northern Iran
por: Sohrabi, Masoudreza, et al.
Publicado: (2023)

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes
por: Doustmohammadian, Azam, et al.
Publicado: (2022)

Are Serum Levels of Nuclear Factor Kappa B and Forkhead Box Protein P3 in Patients with Non-Alcoholic Fatty Liver Disease Related to Severity of Fibrosis?
por: Sohrabi, Masoudreza, et al.
Publicado: (2021)

Glucocorticoid-Induced Fatty Liver Disease
por: Rahimi, Leili, et al.
Publicado: (2020)

Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
por: Hashemi Madani, Nahid, et al.
Publicado: (2020)

Association between Melatonin Value and Interleukins1B, -18, and -33 Levels in Patients with Different Stages of Non-Alcoholic Fatty Liver Disease
por: Sohrabi, Masoudreza, et al.
Publicado: (2022)

The Association of Dietary Intake of Calcium and Vitamin D to Colorectal Cancer Risk among Iranian Population
por: Hosseinzadeh, Payam, et al.
Publicado: (2019)

Concurrent Collagenous Gastritis and Collagenous Colitis: A Case Presentation and Review of the Literature
por: Ziaei, Hossein, et al.
Publicado: (2022)

Association between Helicobacter pylori and Serum Leptin in Iranian Dyspeptic Patients
por: Hemmasi, Gholamreza, et al.
Publicado: (2013)

Can Hepatitis E Virus Be Considered as an Etiology of Cryptogenic Cirrhosis?
por: Sohrabi, Masoudreza, et al.
Publicado: (2014)

Rural Residency has a Protective Effect and Marriage is a Risk Factor for NAFLD
por: Motamed, Nima, et al.
Publicado: (2016)

Hepatic steatosis and liver fat contents in liver transplant recipients are associated with serum adipokines and insulin resistance
por: Eshraghian, Ahad, et al.
Publicado: (2020)

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
por: Packer, Milton, et al.
Publicado: (2023)

Correlation of Tissue Transglutaminase Antibody with Duodenal Histologic Marsh Grading
por: Rahmati, Atieh, et al.
Publicado: (2014)

Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial
por: Gohari, Sepehr, et al.
Publicado: (2021)

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
por: Gharaibeh, Naser Eddin, et al.
Publicado: (2019)

Litchi-Derived Polyphenol Alleviates Liver Steatosis and Gut Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double-Blinded, Placebo-Controlled Study
por: Jinato, Thananya, et al.
Publicado: (2022)

Clinical Manifestations and Diagnosis of Nonalcoholic Fatty Liver Disease
por: Khoonsari, Mahmoodreza, et al.
Publicado: (2017)

The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
por: Gohari, Sepehr, et al.
Publicado: (2022)

Pattern of body mass index, chronic diseases, and physical component of quality of life in a population in North of Iran: A latent class analysis
por: Gholami, Ali, et al.
Publicado: (2018)

Comparison of the efficacy of oral fenugreek seeds hydroalcoholic extract versus placebo in nonalcoholic fatty liver disease; a randomized, triple-blind controlled pilot clinical trial
por: Babaei, Amirhossein, et al.
Publicado: (2020)

Update of liver fibrosis and steatosis with transient elastography (Fibroscan)
por: Wong, Grace Lai-Hung
Publicado: (2013)

The effect of steatosis and fibrosis on blunt force vulnerability of the liver
por: Simon, Gábor, et al.
Publicado: (2020)

Hepatorenal index for grading liver steatosis with concomitant fibrosis
por: Stahlschmidt, Fabio Lucio, et al.
Publicado: (2021)

Association between hypertension and the prevalence of liver steatosis and fibrosis
por: Fu, Huanjie, et al.
Publicado: (2023)

Human liver organoid: modeling liver steatosis and beyond
por: Wei, Jinsong, et al.
Publicado: (2023)

Identifying the pattern of unhealthy dietary habits among an Iranian population: A latent class analysis
por: Gholami, Ali, et al.
Publicado: (2018)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
por: Niu, Shu, et al.
Publicado: (2023)

The association of dietary inflammatory index (DII) and central obesity with non-alcoholic fatty liver disease (NAFLD) in people with diabetes (T2DM)
por: Soltanieh, Samira, et al.
Publicado: (2023)

Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis
por: Radlinger, Bernhard, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hrj7722akuejijpv6hhnjvr5c3